{"id":100916,"date":"2025-01-19T11:00:00","date_gmt":"2025-01-19T16:00:00","guid":{"rendered":"https:\/\/en.econostrum.info\/?p=100916"},"modified":"2025-01-19T06:42:53","modified_gmt":"2025-01-19T11:42:53","slug":"rising-tariff-threaten-u-s-access-to-medicines","status":"publish","type":"post","link":"https:\/\/en.econostrum.info\/rising-tariff-threaten-u-s-access-to-medicines\/","title":{"rendered":"Rising Tariff Costs Threaten U.S. Access to Essential Medicines"},"content":{"rendered":"\n
As Donald Trump prepares to assume the presidency on January 20, 2025, the healthcare industry<\/strong> faces a period of potential upheaval. From rising tariffs <\/strong>to drug pricing reforms<\/strong>, the administration\u2019s policy shifts could bring sweeping changes to how Americans access and afford care.<\/p>\n\n\n\n The sector is keeping a careful eye on the political climate, since billions of dollars and important policy discussions are at risk. Analysts and investors may become alarmed if Trump’s pro-business views clash with bipartisan attempts to control foreign pharmaceutical participation and lower domestic medicine prices.<\/p>\n\n\n\n China is a crucial component of the global pharmaceutical supply chain <\/strong>and a growing market for American companies. In 2021, China held 12%<\/strong> of the world’s pharmaceutical market, and big businesses like Merck, Johnson & Johnson, <\/strong>and AstraZeneca <\/strong>depend significantly on this sector for their financial success. The region is also crucial for the production of active pharmaceutical ingredients<\/strong> (APIs), which are the fundamental components of many different types of drugs and biopharmaceutical products.<\/p>\n\n\n\n Since 2020, U.S. pharmaceutical imports from China<\/a> have surged 485%<\/strong>, climbing from $2.1 billion to $10.3 billion by 2023<\/strong>. However, proposed legislation like the Biosecure Act<\/a>, which would restrict entities receiving federal funding from engaging with Chinese companies, could disrupt this critical flow. Analysts suggest the Act’s passage is unlikely, given the resistance from pharmaceutical firms that rely on China’s cost-effective manufacturing capabilities to cut production expenses by up to 60%<\/strong>.<\/p>\n\n\n\nChina\u2019s Role in Pharmaceuticals: Critical Yet Controversial<\/h2>\n\n\n\n